ClinicalTrials HQ

Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC

Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC

Active, not recruiting · NCT03616886 · Registry updated 2026-10-07
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBCNeoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinomaActive, not recruitingPhase 1 / Phase 22026-10-07NCT03616886

2 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
AstraZeneca806
Jules Bordet Institute39

16 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Centre Antoine LacassagneNiceFrance60
Centre Georges François LeclercDijonFrance35
Centre Henri BecquerelRouenFrance71
CHU BesançonBesançonFrance32
CHU PoitiersPoitiersFrance21
CHU UCL Namur Sainte-ElisabethNamurBelgium2
Clinique St PierreOttigniesBelgium1
Cliniques universitaires Saint LucBrusselsBelgium5
Grand Hôpital de CharleroiCharleroiBelgium6
Hôpitaux Universitaires de StrasbourgStrasbourgFrance24
Institut BergoniéBordeauxFrance47
Institut CurieParisFrance44
Institut Jules BordetBrusselsBelgium18
Institut Paoli-CalmettesMarseilleFrance23
Sint-Augustinus, GZA ZiekenhuizenWilrijkBelgium1
UZ Leuven GasthuisbergLeuvenBelgium6